Table 3.
Association of characteristics of the nummular headache with complete resolution after treatment
| Characteristics | Resolution (yes) | Resolution (no) | P value |
| Age (years; median ±SE; IQR) | 47±2.5 (33–56) | 49±2.9 (41–63) | 0.1835 |
| Gender | 0.1648 | ||
| Male | 14 (35%) | 15 (51.72%) | |
| Female | 26 (65%) | 14 (48.28%) | |
| Latency from the first attack to diagnosis (months; median ±SE) | 12±8.67 | 24±32.14 | 0.0249 |
| Age of onset of pain (years; median ±SE) | 41±2.73 | 43±2.96 | 0.9337 |
| Intensity of pain (VRS 1–10; median ±SE) | 6±0.25 | 5.5±0.32 | 0.6991 |
| Diameter of the pain (cm; median ±SE) | 4±0.23 | 4±0.30 | 0.2054 |
| Number of attacks per day (median ±SE) | 4±2.9 | 3±2.5 | 0.6191 |
| Frequency (days/month; median ±SE) | 19.5±5.49 | 9.5±1.70 | 0.1659 |
| Duration of attacks (min) | 0.0833 | ||
| <30 | 11 (64.71%) | 5 (38.46%) | |
| 30–120 | 5 (29.41%) | 3 (23.08%) | |
| >120 | 1 (5.88%) | 5 (38.46%) | |
| Temporary relief of headache | <0.0001 | ||
| Yes | 35 (87.50%) | 12 (42.86%) | |
| No | 5 (12.50%) | 16 (57.14%) | |
| Onabotulinum toxin A (BoNT-A) | 0.0024 | ||
| Yes | 12 (30%) | 0 (0%) | |
| No | 28 (70%) | 25 (100%) | |
| Triptan | 0.5554 | ||
| Yes | 1 (2.56%) | 2 (8%) | |
| No | 38 (97.44%) | 23 (92.00%) | |
| Tricyclic antidepressant (TCA)* | 0.1356 | ||
| Yes | 4 (7.50%) | 5 (20%) | |
| No | 37 (92.50%) | 20 (80%) | |
| Lamotrigine | 0.0002 | ||
| Yes | 0 (0%) | 8 (32%) | |
| No | 40 (100%) | 17 (68%) | |
| Gabapentin | 0.1163 | ||
| Yes | 24 (60%) | 10 (40%) | |
| No | 16 (40%) | 15 (60%) | |
| Carbamazepine | <0.0001 | ||
| Yes | 1 (2.50%) | 10 (40%) | |
| No | 39 (97.50%) | 15 (60%) |
Note that all percentages are column percentages to compare characteristics between complete resolution and no-resolution groups.
Missing data were not considered for the calculation of the frequency percentages.
*TCA includes amitriptyline and nortriptyline.
BoNT-A, botulinum toxin type A; VRS, verbal rating scale (intensity 1=least severe to 10=most severe).